Loading...
XNASCORT
Market cap5.42bUSD
Jan 08, Last price  
51.69USD
1D
0.86%
1Q
14.23%
Jan 2017
611.98%
Name

Corcept Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CORT chart
P/E
51.03
P/S
11.23
EPS
1.01
Div Yield, %
0.00%
Shrs. gr., 5y
-2.48%
Rev. gr., 5y
13.93%
Revenues
482m
+20.04%
00294,000482,000209,00029,000003,307,00010,357,00026,551,00050,286,00081,321,000159,201,000251,247,000306,486,000353,874,000365,978,000401,858,000482,375,000
Net income
106m
+4.66%
-15,534,481-20,093,000-24,873,000-11,573,000-20,061,000-20,166,000-25,966,000-32,354,000-38,048,000-46,011,000-31,383,000-6,408,0008,140,000129,122,00075,410,00094,181,000106,011,000112,512,000101,418,000106,140,000
CFO
127m
+5.58%
-13,717,923-17,234,000-23,238,000-10,964,000-18,362,000-17,968,000-22,285,000-27,400,000-36,020,000-37,058,000-27,376,0003,130,00018,391,00060,935,000115,665,000136,117,000151,970,000167,892,000120,323,000127,039,000
Earnings
Feb 13, 2025

Profile

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
URL
https://www.corcept.com/
IPO date
Apr 15, 2004
Employees
299
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
482,375
20.04%
401,858
9.80%
Cost of revenue
190,834
136,376
Unusual Expense (Income)
NOPBT
291,541
265,482
NOPBT Margin
60.44%
66.06%
Operating Taxes
18,417
14,773
Tax Rate
6.32%
5.56%
NOPAT
273,124
250,709
Net income
106,140
4.66%
101,418
-9.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
(139,617)
(17,284)
BB yield
3.85%
0.73%
Debt
Debt current
302
1,143
Long-term debt
151
2,286
Deferred revenue
Other long-term liabilities
10,307
7,954
Net debt
(424,944)
(438,137)
Cash flow
Cash from operating activities
127,039
120,323
CAPEX
(139)
(413)
Cash from investing activities
90,906
(114,327)
Cash from financing activities
(148,723)
(17,284)
FCF
273,952
299,588
Balance
Cash
368,221
436,619
Long term investments
57,176
4,947
Excess cash
401,278
421,473
Stockholders' equity
403,268
295,648
Invested Capital
116,036
207,248
ROIC
168.97%
116.82%
ROCE
56.36%
52.79%
EV
Common stock shares outstanding
111,742
115,966
Price
32.48
59.92%
20.31
2.58%
Market cap
3,629,380
54.10%
2,355,269
-5.57%
EV
3,204,436
1,917,132
EBITDA
293,903
268,451
EV/EBITDA
10.90
7.14
Interest
3,557
Interest/NOPBT
1.34%